J. E. Rosenberg

Phase II trial of sunitinib in bevacizumab-refractory metastatic renal cell carcinoma (mRCC): Updated results and analysis of circulating biomarkers

Daniel J. George, M. Dror Michaelson, J. E. Rosenberg et al. · Journal of Clinical Oncology · 2007 · 48 citations

Urology, Angiogenesis, Phase Ii Trial +13

A phase II study of the dual MET/VEGFR2 inhibitor XL880 in patients (pts) with papillary renal carcinoma (PRC)

Ramprasad Srinivasan, Toni K. Choueiri, Ulka N. Vaishampayan et al. · Journal of Clinical Oncology · 2008 · 48 citations

Pathology, Phase Ii Study, Pharmacotherapy +18

Defining “cisplatin ineligible” patients with metastatic bladder cancer.

Matthew D. Galsky, Noah M. Hahn, J. E. Rosenberg et al. · Journal of Clinical Oncology · 2011 · 26 citations

Cisplatin-ineligible Pts, Urology, Cisplatin-based Chemotherapy +13

Lack of Effectiveness of Postchemotherapy Lymphadenectomy in Bladder Cancer Patients with Clinical Evidence of Metastatic Pelvic or Retroperitoneal Lymph Nodes Only: A Propensity Score-based Analysis

Andrea Necchi, Luigi Mariani, Salvatore Lo Vullo et al. · European Urology Focus · 2017 · 20 citations

Propensity Score-based Analysis, Urological Research, Urology +8

Impact of prior ketoconazole therapy on response proportion to abiraterone acetate, a 17-alpha hydroxylase C17,20-lyase inhibitor in castration resistant prostate cancer (CRPC)

Charles J. Ryan, Matthew Smith, J. E. Rosenberg et al. · Journal of Clinical Oncology · 2008 · 19 citations

Pharmacotherapy, Experimental Pharmacology, Pre-clinical Pharmacology +21